An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Agilent Wins Two Scientists’ Choice Awards for Drug Discovery and Development Products
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) has received two prestigious awards from SelectScience for Best New Drug Discovery & Development Product of 2023 and Drug Discovery & Development Webinar of the Year. The awards highlight Agilent's commitment to innovation and excellence in drug discovery and development. The Agilent xCELLigence RTCA HT-BioTek BioSpa 8 - Screening Model won the Best New Drug Discovery & Development Product of 2023. The Drug Discovery & Development Webinar of the Year was co-produced between Agilent and Dr. Agapitos Patakas, Chief Scientific Officer, Antibody Analytics. The awards were presented at the 2024 SLAS International Conference and Exhibition in Boston, Massachusetts, and recognize innovative and effective technologies advancing drug discovery and development in 2023.
Positive
None.
Negative
None.
SANTA CLARA, Calif.--(BUSINESS WIRE)--
Agilent Technologies Inc. (NYSE: A) announced today that it has received two prestigious awards from SelectScience: Best New Drug Discovery & Development Product of 2023 and Drug Discovery & Development Webinar of the Year. These accolades highlight Agilent’s commitment to innovation and excellence in drug discovery and development.
The Agilent xCELLigence RTCA HT-BioTek BioSpa 8 – Screening Model was voted Best New Drug Discovery & Development Product of 2023. The Agilent xCELLigence RTCA HT-BioTek BioSpa 8 integrates the xCELLigence Real-Time Cell Analyzer (RTCA) HT instrument with the BioTek BioSpa 8 automated incubator to expand the screening throughput of your RTCA HT instrument to eight 384-well plates. Label-free high-throughput xCELLigence Real-Time Cell Analysis is ideal for screening viral-mediated cytopathic effects (CPE), neutralizing antibodies, antibody-dependent cytotoxicity (ADCC), and compound-mediated cytotoxicity.
“We are honored and delighted to receive these awards from SelectScience and the scientific community,” said Todd Christian, vice president and general manager of Agilent’s Cell Analysis Division. “These awards reflect our commitment to providing innovative and reliable solutions that empower our customers to advance scientific discoveries and improve human health.”
The awards were presented at the 2024 SLAS International Conference and Exhibition in Boston, Massachusetts, and recognize the most innovative and effective technologies advancing drug discovery and development in 2023.
The Scientists’ Choice Awards celebrate the laboratory products and manufacturers that make a difference to the industry. Scientists around the world choose the winners through online voting and reviews.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
What awards did Agilent Technologies Inc. (NYSE: A) receive from SelectScience?
Agilent Technologies Inc. (NYSE: A) received the Best New Drug Discovery & Development Product of 2023 and Drug Discovery & Development Webinar of the Year awards from SelectScience.
What is the Agilent xCELLigence RTCA HT-BioTek BioSpa 8 - Screening Model?
The Agilent xCELLigence RTCA HT-BioTek BioSpa 8 - Screening Model won the Best New Drug Discovery & Development Product of 2023 award. It integrates the xCELLigence Real-Time Cell Analyzer (RTCA) HT instrument with the BioTek BioSpa 8 automated incubator to expand the screening throughput of the RTCA HT instrument to eight 384-well plates.
Who co-produced the Drug Discovery & Development Webinar of the Year with Agilent?
The Drug Discovery & Development Webinar of the Year was co-produced between Agilent and Dr. Agapitos Patakas, Chief Scientific Officer, Antibody Analytics.
Where were the awards presented?
The awards were presented at the 2024 SLAS International Conference and Exhibition in Boston, Massachusetts.
How were the winners of the awards chosen?
The winners of the awards were chosen through online voting and reviews by scientists around the world.
analytical scientists and clinical researchers worldwide rely on agilent to help fulfill their most complex laboratory demands. our instruments, software, services and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us. whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals or food testing, agilent provides laboratory solutions to meet their full spectrum of needs. we work closely with customers to help address global trends that impact human health and the environment, and to anticipate future scientific needs. our solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management. customers trust agilent for solutions that enable insights...for a better world.
